Skip to content

CorMedix CRMD Manufacturing related

Manufacturing related at other companies

Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
$829K+74.2%
Vaxcyte, Inc. logo
Vaxcyte, Inc.PCVX
$0
Consolidated Water Company logo
Consolidated Water CompanyCWCO
$105.96K-93.5%
Ardelyx logo
ArdelyxARDX
$18.9M+10.5%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$72.79M-64.2%
AXT
AXTAXTI
$1.4M

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept crmd:ManufacturingDevelopmentCurrent.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's manufacturing related.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's manufacturing related?
CorMedix (CRMD) reported manufacturing related of $2.08M in Q1 2026.
How has CorMedix's manufacturing related changed year-over-year?
CorMedix's manufacturing related increased by 829.9% year-over-year, from $223.58K to $2.08M.
What is the long-term trend for CorMedix's manufacturing related?
Over 3 years (2022 to 2025), CorMedix's manufacturing related has grown at a -23.4% compound annual growth rate (CAGR), from $1.21M to $546K.
What does manufacturing related mean?
This represents current costs or liabilities associated with the manufacturing development process, including scale-up activities, process validation, or contract manufacturing arrangements. It reflects the company's investment in transitioning from clinical development to commercial-scale production. Tracking these costs provides insight into the company's operational readiness for product commercialization.